Abbott Defeated In HCV Patent Spat

Law360, New York (January 4, 2007, 12:00 AM EST) -- In a blow to Abbott Laboratories, a federal judge has upheld a jury’s decision to award Belgian biotechnology company Innogenetics NV $7 million in damages in the duo’s long-standing battle over a hepatitis C virus genotyping patent.

On Thursday, Innogenetics revealed that a Wisconsin district judge had sustained the jury’s earlier verdict and damages award, hailing the decision as a victory for innovators.

"Today's ruling sends a message to companies large and small that mistakenly believe they can misappropriate others' innovations without regard for the law,"...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.